Pliant Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Pliant Therapeutics's earnings are forecast to decline at 2.5% per annum while its annual revenue is expected to grow at 70.9% per year. EPS is expected to grow by 5.8% per annum. Return on equity is forecast to be -70.8% in 3 years.

Wichtige Informationen

-2.5%

Wachstumsrate der Gewinne

5.8%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	70.9%
Zukünftige Eigenkapitalrendite	-70.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	23 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22

We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Jan 21

Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Dec 17

Pliant Therapeutics (PLRX) Presents At Piper Sandler 32nd Annual Virtual Healthcare Conference - Slideshow

Dec 02

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:PLRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	4	-275	-235	-219	10
12/31/2025	6	-245	-199	-196	13
12/31/2024	2	-208	-142	-160	13
3/31/2024	0	-171	-119	-116	N/A
12/31/2023	2	-161	-117	-116	N/A
9/30/2023	4	-155	-124	-122	N/A
6/30/2023	5	-144	-106	-105	N/A
3/31/2023	10	-133	-106	-104	N/A
12/31/2022	10	-123	-96	-95	N/A
9/30/2022	10	-113	-85	-83	N/A
6/30/2022	10	-109	-89	-87	N/A
3/31/2022	7	-103	-85	-82	N/A
12/31/2021	8	-97	-77	-75	N/A
9/30/2021	10	-92	-74	-72	N/A
6/30/2021	13	-81	-67	-65	N/A
3/31/2021	15	-75	-40	-38	N/A
12/31/2020	42	-42	-39	-37	N/A
9/30/2020	94	18	15	16	N/A
6/30/2020	90	19	16	17	N/A
3/31/2020	86	20	-6	-5	N/A
12/31/2019	57	-7	-4	-3	N/A
3/31/2019	N/A	-43	-33	-32	N/A
12/31/2018	N/A	-35	-31	-28	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PLRX is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: PLRX is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: PLRX is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: PLRX's revenue (70.9% per year) is forecast to grow faster than the US market (8.7% per year).

Hohe Wachstumseinnahmen: PLRX's revenue (70.9% per year) is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: PLRX is forecast to be unprofitable in 3 years.

Pliant Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates decrease by 69%, EPS upgraded

Price target decreased by 7.1% to US$42.67

Price target decreased by 9.4% to US$44.08

Consensus revenue estimates decrease by 20%, EPS upgraded

Consensus revenue estimates fall by 32%

Consensus revenue estimates increase by 11%

Recent updates

Pliant Therapeutics, Inc. Appoints Steve Krognes to Its Board of Directors

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Pliant Therapeutics, Inc. Announces Positive Topline Data from A Phase 2A Collagen Pet Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis

First quarter 2024 earnings released: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)

Pliant Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis

New major risk - Revenue and earnings growth

Consensus revenue estimates decrease by 69%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 7.1% to US$42.67

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Price target decreased by 9.4% to US$44.08

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Consensus revenue estimates decrease by 20%, EPS upgraded

Third quarter 2023 earnings released: US$0.69 loss per share (vs US$0.65 loss in 3Q 2022)

Pliant Therapeutics, Inc. Appoints S. Mishima Gerhart as Chief Regulatory Officer

Pliant Therapeutics, Inc. Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics, Inc. Appoints Minnie Kuo as Chief Development Officer

Consensus revenue estimates fall by 32%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chief Business Officer notifies of intention to sell stock

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Pliant Therapeutics, Inc. Presents Data from Its Bexotegrast Program At the European Association for the Study of the Liver International Liver Congress

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 123%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel & Corporate Secretary notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

President notifies of intention to sell stock

Pliant Therapeutics, Inc. Appoints Lily Cheung as Chief Human Resources Officer

Price target increased by 17% to US$49.09

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial

President notifies of intention to sell stock

Insufficient new directors

General Counsel & Corporate Secretary notifies of intention to sell stock

Pliant Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

Neil Exter to Retire as Member of the Board of Directors of Pliant Therapeutics

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options and sold US$256k worth of stock

Pliant Therapeutics Appoints Katharine Knobi to Board of Directors

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Pliant Therapeutics: Wait For A Better Price To Get In

Consensus revenue estimates increase by 48%

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant Therapeutics Receives FDA Fast Track Designation for Pln-74809 for the Treatment of Primary Sclerosing Cholangitis

Pliant's PLN-74809 gets FDA fast track status for liver disease

Price target increased to US$43.71

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Pliant Therapeutics, Inc. Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

Pliant Therapeutics, Inc.(NasdaqGS:PLRX) dropped from Russell 2000 Growth Index

Pliant Therapeutics Presents Preclinical Data Highlighting A Novel Approach for the Treatment of Muscular Dystrophies

Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration

Pliant: Major Catalyst Expected Beginning Of 2023

Pliant Therapeutics, Inc. Presents Five Scientific Posters as Part of the 2022 American Thoracic Society International Conference

Price target decreased to US$39.67

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pliant Therapeutics, Inc., Annual General Meeting, Jun 16, 2022

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-ß Signaling in Healthy Volunteers

Pliant Therapeutics, Inc. Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis